Advertisement

A series of cases with Huntington-like phenotype and intermediate repeats in HTT

Published:April 15, 2021DOI:https://doi.org/10.1016/j.jns.2021.117452

      Highlights

      • We describe the larger series of clinical cases (n = 14) with HD-like phenotype and IAs published to date.
      • MRI and FDG-PET neuroimaging findings compatible with HD can be found in some patients with IA.
      • Larger and more detailed series are needed to assess the pathogenic role of IAs in HTT gene.

      Abstract

      Background

      Intermediate Alleles (IAs) are expansions of CAG repeats in the HTT gene between 27 and 35 repeats which pathogenic meaning remains controversial. They are present in the general population but there is an increasing number of cases with Huntington-like phenotype reported.

      Methods

      We reviewed the medical records of cases in our centre where the neurologist suspected Huntington's disease (HD) as one of the feasible diagnoses and genetic testing showed the number of CAG repeats was in the “intermediate range”. We gathered the type of symptoms in all cases and the main neuroimaging findings when available.

      Results

      We found 14 cases, 8 males and 6 females, with average age at onset at 64 years old. Most cases exhibited some type of extrapyramidal symptoms. Cognitive and/or behavioral symptoms were also present in most cases (being depression, anxiety and cognitive impairment the most frequent ones). In one case we found deposits of iron in the basal ganglia in the MRI, and in another case we found diffuse cortical hypometabolism with predominantly frontal bilateral involvement and bilateral focal deficit of both caudate and thalamus in the FDG-PET.

      Conclusion

      The clinical and neuroimaging findings of some cases with IA in this series are compatible with the clinical picture of HD but also with several other alternative diagnoses. Therefore we can not establish association between IA and HD. Larger series with more comprehensive diagnostic workout and neuropathological studies are needed to confirm or rule out whether IAs in the HTT gene may cause HD.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Cardoso F.
        Nonmotor symptoms in Huntington disease.
        Int. Rev. Neurobiol. 2017; 134: 1397-1408
        • Paulsen J.S.
        Cognitive impairment in Huntington disease: diagnosis and treatment.
        Curr. Neurol. Neurosci. Rep. 2011; 11: 474-483
        • Apolinário T.A.
        • Paiva C.L.
        • Agostinho L.A.
        Intermediate alleles of Huntington’s disease HTT gene in different populations worldwide: a systematic review.
        Genet. Mol. Res. 2017; 16
        • Gardiner S.L.
        • Boogaard M.W.
        • Trompet S.
        • et al.
        Prevalence of carriers of intermediate and pathological polyglutamine disease-associated alleles among large population-based cohorts.
        JAMA Neurol. 2019; 76: 650-656
        • Bürger K.
        • Mergner R.
        • Arbusow V.
        • Padberg F.
        • Hampel H.
        Late onset Huntington’s disease - a differential diagnosis of Alzheimer’s disease.
        Nervenarzt. 2002; 73: 870-873
        • Dewan R.
        • Chia R.
        • Ding J.
        • et al.
        Pathogenic Huntingtin repeat expansions in patients with frontotemporal dementia and amyotrophic lateral sclerosis.
        Neuron. 2021 Feb 3; 109 (e4): 448-460
        • Cubo E.
        • Ramos-Arroyo M.A.
        • Martinez-Horta S.
        • et al.
        Clinical manifestations of intermediate allele carriers in Huntington disease.
        Neurology. 2016; 87: 571-578
        • Andrich J.
        • Arning L.
        • Wieczorek S.
        • et al.
        Huntington’s disease as caused by 34 CAG repeats.
        Mov. Disord. 2008; 23: 879-881
        • Groen J.L.
        • de Bie R.M.
        • Foncke E.M.
        • et al.
        Late-onset Huntington disease with intermediate CAG repeats: true or false?.
        J. Neurol. Neurosurg. Psychiatry. 2010; 81: 228-230
        • Ha A.D.
        • Jankovic J.
        Exploring the correlates of intermediate CAG repeats in Huntington disease.
        Postgrad. Med. 2011; 123 (116–2)
        • Herishanu Y.O.
        • Parvari R.
        • Pollack Y.
        • et al.
        Huntington disease in subjects from an Israeli Karaite community carrying alleles of intermediate and expanded CAG repeats in the HTT gene: Huntington disease or phenocopy?.
        J. Neurol. Sci. 2009; 277: 143-146
        • Killoran A.
        • Biglan K.M.
        • Jankovic J.
        • et al.
        Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS.
        Neurology. 2013; 80: 2022-2027
        • Kenney C.
        • Powell S.
        • Jankovic J.
        Autopsy-proven Huntington’s disease with 29 trinucleotide repeats.
        Mov. Disord. 2007 Jan; 22: 127-130
        • Savitt D.
        • Jankovic J.
        Clinical phenotype in carriers of intermediate alleles in the huntingtin gene.
        J. Neurol. Sci. 2019; 402: 57-61
        • Domínguez J.F.
        • Ng A.C.
        • Poudel G.
        • et al.
        Iron accumulation in the basal ganglia in Huntington’s disease: cross-sectional data from the IMAGE-HD study.
        J. Neurol. Neurosurg. Psychiatry. 2016; 87: 545-549
        • Bartzokis G.
        • Tishler T.A.
        MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer’s and Huntingon’s disease.
        Cell. Mol. Biol. (Noisy-le-grand). 2000; 46: 821-833
        • Muller M.
        • Leavitt B.R.
        Iron dysregulation in Huntington’s disease.
        J. Neurochem. 2014; 130: 328-350
        • Bartzokis G.
        • Cummings J.
        • Perlman S.
        • Hance D.B.
        • Mintz J.
        Increased basal ganglia iron levels in Huntington disease.
        Arch. Neurol. 1999; 56: 569-574
        • Jurgens C.K.
        • Jasinschi R.
        • Ekin A.
        • et al.
        MRI T2 Hypointensities in basal ganglia of premanifest Huntington’s disease.
        PLoS Curr. 2010; 2RRN1173
        • van Bergen J.M.
        • Hua J.
        • Unschuld P.G.
        • et al.
        Quantitative susceptibility mapping suggests altered brain iron in premanifest Huntington disease.
        AJNR Am. J. Neuroradiol. 2016; 37: 789-796
        • Dumas E.M.
        • Versluis M.J.
        • van den Bogaard S.J.
        • et al.
        Elevated brain iron is independent from atrophy in Huntington’s disease.
        Neuroimage. 2012; 61: 558-564
        • Pagano G.
        • Niccolini F.
        • Politis M.
        Current status of PET imaging in Huntington’s disease.
        Eur. J. Nucl. Med. Mol. Imaging. 2016; 43: 1171-1182
        • Feigin A.
        • Leenders K.L.
        • Moeller J.R.
        • Missimer J.
        • Kuenig G.
        • Spetsieris P.
        • Antonini A.
        • Eidelberg D.
        Metabolic network abnormalities in early Huntington’s disease: an [(18)F]FDG PET study.
        J. Nucl. Med. 2001; 42: 1591-1595